FI971675L - Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi - Google Patents
Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi Download PDFInfo
- Publication number
- FI971675L FI971675L FI971675A FI971675A FI971675L FI 971675 L FI971675 L FI 971675L FI 971675 A FI971675 A FI 971675A FI 971675 A FI971675 A FI 971675A FI 971675 L FI971675 L FI 971675L
- Authority
- FI
- Finland
- Prior art keywords
- related conditions
- inhibiting bradykinin
- bradykinin
- inhibiting
- conditions
- Prior art date
Links
- 101800004538 Bradykinin Proteins 0.000 title 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 title 1
- 102100035792 Kininogen-1 Human genes 0.000 title 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/326,672 US5545641A (en) | 1994-10-20 | 1994-10-20 | Methods of inhibiting physiological conditions associated with an excess of bradykinin |
| PCT/US1995/013452 WO1996012491A1 (en) | 1994-10-20 | 1995-10-19 | Method of inhibiting conditions associated with bradykinin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI971675A0 FI971675A0 (fi) | 1997-04-18 |
| FI971675L true FI971675L (fi) | 1997-06-16 |
Family
ID=23273190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI971675A FI971675L (fi) | 1994-10-20 | 1997-04-18 | Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5545641A (fi) |
| EP (1) | EP0782444A4 (fi) |
| JP (1) | JPH10507760A (fi) |
| KR (1) | KR970706819A (fi) |
| AU (1) | AU714789B2 (fi) |
| CA (1) | CA2203914A1 (fi) |
| CZ (1) | CZ119197A3 (fi) |
| FI (1) | FI971675L (fi) |
| HU (1) | HUT77765A (fi) |
| IL (1) | IL115614A (fi) |
| MY (1) | MY113406A (fi) |
| NO (1) | NO971794L (fi) |
| NZ (1) | NZ296285A (fi) |
| RU (1) | RU2181047C2 (fi) |
| WO (1) | WO1996012491A1 (fi) |
| ZA (1) | ZA958683B (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0747051B1 (en) * | 1995-06-07 | 2002-07-24 | Eli Lilly And Company | Treatment of diseases by inducing BEF-1 transcription factor |
| US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
| US6113876A (en) * | 1996-01-29 | 2000-09-05 | Eli Lilly And Company | Methods of increasing sphincter competence |
| DE19620508A1 (de) * | 1996-05-22 | 1997-11-27 | Hoechst Ag | Schwefelenthaltende heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
| ES2246234T3 (es) | 1999-05-04 | 2006-02-16 | Strakan International Limited | Glicosidos de androgenos y actividad androgenica de los mismos. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4703053A (en) * | 1985-10-28 | 1987-10-27 | Warner-Lambert Company | Benzothiophenes and benzofurans and antiallergic use thereof |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US4931459A (en) * | 1987-07-14 | 1990-06-05 | Warner-Lambert Company | Method for treating acute respirator distress syndrome |
| US4910317A (en) * | 1987-07-14 | 1990-03-20 | Warner-Lambert Company | Benzofurans and benzothiophenes having antiallergic activity and method of use thereof |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| US5441965A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
| US5574047A (en) * | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
| US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5521198A (en) * | 1993-12-21 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting autoimmune diseases |
-
1994
- 1994-10-20 US US08/326,672 patent/US5545641A/en not_active Expired - Fee Related
-
1995
- 1995-10-13 ZA ZA958683A patent/ZA958683B/xx unknown
- 1995-10-13 IL IL11561495A patent/IL115614A/xx not_active IP Right Cessation
- 1995-10-19 JP JP8514050A patent/JPH10507760A/ja active Pending
- 1995-10-19 HU HU9800904A patent/HUT77765A/hu unknown
- 1995-10-19 CZ CZ971191A patent/CZ119197A3/cs unknown
- 1995-10-19 WO PCT/US1995/013452 patent/WO1996012491A1/en not_active Application Discontinuation
- 1995-10-19 KR KR1019970702592A patent/KR970706819A/ko not_active Application Discontinuation
- 1995-10-19 EP EP95938795A patent/EP0782444A4/en not_active Withdrawn
- 1995-10-19 RU RU97107855/14A patent/RU2181047C2/ru active
- 1995-10-19 AU AU40039/95A patent/AU714789B2/en not_active Ceased
- 1995-10-19 CA CA002203914A patent/CA2203914A1/en not_active Abandoned
- 1995-10-19 NZ NZ296285A patent/NZ296285A/xx unknown
- 1995-10-20 MY MYPI95003157A patent/MY113406A/en unknown
-
1997
- 1997-04-18 NO NO971794A patent/NO971794L/no not_active Application Discontinuation
- 1997-04-18 FI FI971675A patent/FI971675L/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0782444A1 (en) | 1997-07-09 |
| ZA958683B (en) | 1997-04-14 |
| KR970706819A (ko) | 1997-12-01 |
| IL115614A0 (en) | 1996-01-19 |
| NZ296285A (en) | 2000-08-25 |
| NO971794L (no) | 1997-05-22 |
| FI971675A0 (fi) | 1997-04-18 |
| MX9702861A (es) | 1997-07-31 |
| RU2181047C2 (ru) | 2002-04-10 |
| JPH10507760A (ja) | 1998-07-28 |
| NO971794D0 (no) | 1997-04-18 |
| AU4003995A (en) | 1996-05-15 |
| US5545641A (en) | 1996-08-13 |
| AU714789B2 (en) | 2000-01-13 |
| IL115614A (en) | 1999-08-17 |
| WO1996012491A1 (en) | 1996-05-02 |
| CA2203914A1 (en) | 1996-05-02 |
| CZ119197A3 (en) | 1997-11-12 |
| MY113406A (en) | 2002-02-28 |
| EP0782444A4 (en) | 2002-01-30 |
| HUT77765A (hu) | 1998-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69534965D1 (de) | Abscheidungsverfahren | |
| FI963597L (fi) | Isoprenyylitransferaasi-inhibiittoreita | |
| NO972930D0 (no) | Fibronectin-adhesjonsinhibitorer | |
| FI951596L (fi) | Menetelmä 10-desasetyylibakkatiini-III:n saamiseksi | |
| FI972160A0 (fi) | Matriisimetalloproteaasi-inhibiittorit | |
| FI954863A (fi) | Parannettu menetelmä polymeerien muodostamiseksi | |
| FI972318A0 (fi) | Menetelmä ikkunan irrottamiseksi | |
| FI954423L (fi) | Menetelmä taksoidien puhdistamiseksi | |
| KR960012337A (ko) | 에칭방법 | |
| BR9500653A (pt) | Método de combustão | |
| FI962069L (fi) | Menetelmä karpolaktaamin valmistamiseksi | |
| FI971426L (fi) | Vedenpoistomenetelmä | |
| DE69523060D1 (de) | Luziferase-markierungsmethode | |
| FI970670L (fi) | Polttomenetelmä | |
| KR970001365A (ko) | 알킬하이드로겐클로로실란의 제조방법 | |
| FI953047L (fi) | Menetelmä putkien eristämiseksi | |
| FI20050181L (fi) | Menetelmä valmistaa 21-kloorikortikosteroideja | |
| DE69519583D1 (de) | Schlammentwässerungsverfahren | |
| FI972527L (fi) | Pinnoitusmenetelmä | |
| FI944631L (fi) | Menetelmä jäteveden puhdistamiseksi | |
| FI943107L (fi) | Menetelmä vinassin fraktioimiseksi | |
| FI955800L (fi) | Menetelmä aminoalkyyliganidiinien valmistamiseksi | |
| BR9509015A (pt) | Inibidores de 5alfa-reductase | |
| FI952484L (fi) | Menetelmä metallihydroksidien valmistamiseksi | |
| FI964001L (fi) | Menetelmä 7-trialkyylisilyylibakkatiini III:n valmistamiseksi |